Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. Issue 2 (December 2015)

• Record Type: Journal Article
• Authors: Kim, Soon Sun; Cho, Hyo Jung; Won, Je Hwan; Bae, Jae Ik; Kang, Dae Ryong; Lee, Jung-Dong; Shin, Sung Jae; Lee, Kee Myung; Yoo, Byung Moo; Kim, Jai Keun; Lee, Jei Hee; Ahn, Seon Joo; Park, Ju Han; Cho, Sung Won; Cheong, Jae Youn
• Is Part Of: Cytokine. Volume 76:Issue 2(2015)
• Page Start: 449
• Page End: 457
• Publication Date: 2015-12
• Subjects: Chemoembolization -- Hepatocellular carcinoma -- Interleukin-8 -- Survival -- Treatment failure; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2015.07.001
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: The study measured pretreatment levels of 11 cytokines including IL-8. TACE refractoriness and LT-free survival were evaluated in 119 patients with HCC. Combined AFP and IL-8 levels independently predicted overall TACE refractoriness. High IL-8 level was also associated with poor LT-free survival. Serum IL-8 level is a useful prognostic marker in TACE-treated patients with HCC. Abstract: We investigated the association between serum interleukin (IL)-8 levels and post-transarterial chemoembolization (TACE) outcomes in patients with hepatitis B virus (HBV)-associated HCC. We enrolled 119 TACE-treated patients with HBV-associated HCC; TACE refractoriness and liver transplantation (LT)-free survival were evaluated during follow-up. Pre-TACE serum levels of various cytokines (epidermal growth factor [EGF], fibroblast growth factor 2, granulocyte-colony stimulating factor [G-CSF], interferon-γ, IL-8, IL-12, IL-17A, interferon-γ-inducible protein-10, monocyte chemotactic protein-1, tumor necrosis factor-α and vascular endothelial growth factor) were analyzed. During a mean follow-up of 24.3 (1–79) months, 91 patients (76.5%) exhibited TACE refractoriness. In multivariate analyses, multiple tumors (hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.28–4.39; P = 0.006), large tumor size (HR, 2.36; 95% CI, 1.38–4.03; P = 0.002), and combination of alpha-fetoprotein and IL-8 levels (AFP > 400 ng/mL or IL-8 > 32 pg/mL; HR, 1.72; 95% CI, 1.03–2.85; P = 0.037) independently predicted overall TACE refractoriness. Higher EGF (>35 pg/mL) and lower G-CSF levels (⩽12.5 pg/mL) were associated with early TACE refractoriness (<1 year; HR, 3.47; 95% CI, 1.01–11.96; P = 0.049 and HR, 6.25; 95% CI, 1.62–23.81; P = 0.008, respectively). Furthermore, high IL-8 level (>32 pg/mL; HR, 1.68; 95% CI, 1.09–2.59; P = 0.020) was associated with poor LT-free survival. In conclusion, pretreatment serum IL-8 is a useful prognostic marker for TACE refractoriness and LT-free survival in TACE-treated patients with HBV-associated HCC.